How to Cite
Abstract
To determine mutations in the plasma KRAS gene in patients with colorectal cancer was the aim of this study. The material was obtained from 44 patients with colorectal cancer of different stages (T1-4N0-2bM0-1c). Plasma for the presence of KRAS gene mutation in circulating tumor DNA was investigated using digital droplet polymerase chain reaction (PCR). KRAS mutations in circulating tumor DNA isolated from 1 ml of plasma were detected in 13 (30%) patients with cancer of different stages. Of these, with stage II, there were 3 patients, with III - 5 and with IV - 5. Patients who did not have mutations in 1 ml of plasma were analyzed for mutations of KRAS in circulating tumor DNA isolated from 3 ml of plasma. Five more patients with KRAS mutations were found with II and III stages. The highest concentrations of circulating tumor DNA with KRAS mutation were found in patients with stage IV. The increase in plasma volume to 3 ml did not lead to the identification of mutations in I stage. This study showed that digital droplet PCR allows identification of circulating tumor DNA with the KRAS mutations in patients with stage II-IV of colon cancer. The results can be used to determine the degree of aggressiveness of the tumor at different stages of the disease, but not the 1st, and it is recommended to use a plasma volume of at least 3 ml.References
Власов О.А., Ткачев С.И., Пророков В.В. Колоректальный рак и особенности его метастазирования // Вопросы онкологии. - 2017. - Т. 63. - № 3. - С. 450-455.
Сушков О.И., Ачкасов С.И. Перитонеальный карциноматоз при раке толстой кишки. Подходы к лечению (обзор литературы) // Колопроктология. - 2016. - Т 58. - № 4. - С. 69-79.
Федянин М.Ю., Эльснукаева Х.Х.М., Алиев В.А. и др. Циркулирующая в кровиопухолевая ДНК как маркер резидуальной болезни при раке толстой кишки // Онкологическая колопроктология. - 2018. - Т.8. - № 3. - С. 11-16.
Шелыгин Ю.А., Ачкасов С.И., Сушков О.И. и др. Роль циторедуктивной хирургии и внутрибрюшной интраоперационной химиотерапии в лечении рака толстой кишки с перитонеальным карциноматозом // Колопроктология. - 2017. - Т. 59. - № 1. - С. 53-58.
Шубин В.П., Шелыгин Ю.А., Сушков О.И. и др. Роль эпителиально-мезенхимального перехода в развитии колоректального рака (обзор литературы) // Колопроктология. - 2018. - Т. 64. - № 2. - С. 111-117.
Шубин В.П., Поспехова Н.И., Цуканов А.С. и др. Частота и спектр мутаций в гене KRAs при раке толстой кишки разной локализации и раке анального канала // Медицинская генетика. - 2014. - Т. 13. - № 5. - С. 31-35.
Amin MB., edge s., Greene F. et al. // AJCC Cancer staging Manual. - 2017.
Ashworth т. A case of cancer in which cells similar to those in the tumors were seen in blood after death // Aust. Med. J. - 1869. - Vol.14. - P. 146-147.
Crowley E., Di Nicolantonio F, Loupakis F., et al. Liquid biopsy: monitoring cancer-genetics in the blood // Nat. Rev. Clin. Oncol. - 2013. - Vol. 8. - P 472-84. - DOI: 10.1038/nrclinonc.2013.110
El Messaoudi S., Rolet F, Mouliere F. et al. Circulating cell free DNA: Preanalytical considerations // Clin. Chim. Acta. - 2013. - Vol.424. - P. 222-230.
Imyanitov E.N. Molecular diagnosis in oncology // Molecular Biology. - 2008. - Vol. 42. - № 5. - P. 687-698.
Moon B.S., Jeong W.J., Park J. et al. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/|3-catenin signaling // J Natl Cancer Inst. - 2014. - Vol.106. - P. 373. DOI: 10.1093/jnci/djt373
Nash G.M., Gimbel M., Shia J. et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastasis // Ann. Surg. Oncol. - 2010. - Vol. 17. - P. 572-578.
Nieva J.J., Kuhn P. Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease // Future Oncol. - 2012. - Vol. 8. - P. 989-998. -. DOI: 10.2217/fon.12.91
Nikolaev S., Lemmens L., Koessler T. et al. Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory // Anal. Biochem. - 2018. - Vol. 542. - P. 34-39.
Shabunin АЛ/., Tavobilov М.М., Grekov D.N. et al. Combined modality treatment for patients with inoperable colorecral liver metastases // Siberian Journal of Oncology. - 2018. - Vol.17. - P. 34-40. - DOI: 10.21294/1814-4861-2018-17-3-34-40
Spindler K.G, Appelt A.L, Pallisgaard N. et al. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer // Br. J. Cancer. - 2013. - Vol. 109. - P. 3067-3072. - DOI: 10.1038/bjc.2013.633
Spindler K.L., Pallisgaard N.; Vogelius, I. et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan // Clin. Cancer Res. - 2012. - Vol. 18. - P. 1177-1185.
Tan Y, Wu. H. The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis // Curr. Probl. Cancer. - 2017. - Vol. 42. - P. 95-106. - DOI: 10.1016/j.currprob-lcancer.2017.11.002
Vymetalkova V., Cervena K., Bartu L., et al. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review // Int. J. Mol. Sci. - 2018. - Vol.19. - P. 1-29. - DOI: 10.3390/ijms19113356
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019